Metacard MR (Trimetazidine)

Therapeutic Group : Cardiovascular

Presentation:

Metacard MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.

Indications:

Metacard MR Tablet is a metabolic treatment for ischaemic heart disease. It can be used at all stages of angina pectoris and in post myocardial infarction. Metacard MR therapy has also demonstrated beneficial effects when administered during bypass surgery.

Dosage & Administration:

One tablet at mealtimes in the morning and evening.

Contrainidications:

Trimetazidine is contraindicated in-patients with a known hypersensitivity to its components.

Side effects:

Trimetazidine is safe and well tolerated. Rare cases of gastrointestinal disorders, nausea & vomiting have been reported.

Drug interaction:

No drug interactions so far have been reported. In particular, no interactions have been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidaemic agents or digitalis preparation.

Use in special groups:

Use in Pregnancy: Studies in animals have not demonstrated teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.
Use in Lactation: In the absence of data, breastfeeding is not recommended during treatment.

Packing:

Metacard MR Tablet: Each box contains 60’s tablets in blister pack.